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ABSTRACT
Peripheral lung nodules remain challenging for
accurate localization and diagnosis. Once
identified, there are many strategies for
diagnosis with heterogeneous risk benefit
analysis. Traditional strategies such as
conventional bronchoscopy have poor
performance in locating and acquiring the
required tissue. Similarly, while
computerized-assisted transthoracic needle
biopsy is currently the favored diagnostic
procedure, it is associated with complications
such as pneumothorax and hemorrhage.
Video-assisted thoracoscopic and open surgical
biopsies are invasive, require general anesthesia
and are therefore not a first-line approach. New
techniques such as ultrathin bronchoscopy and
image-based guidance technologies are evolving
to improve the diagnosis of peripheral lung
lesions. Virtual bronchoscopy and
electromagnetic navigation systems are novel
technologies based on assisted-computerized
tomography images that guide the
bronchoscopist toward the target peripheral
lesion. This article provides a comprehensive
review of these emerging technologies.
Keywords: Bronchoscopy; Computerized
tomography (CT); Electromagnetic navigation;
Image guidance; Lung cancer; Peripheral lung
lesion; Respiratory
INTRODUCTION
Lung cancer is the most common cause of
cancer-related death in the USA and worldwide
accounting for more cancer-related deaths
compared to colon, breast and prostate
combined [1, 2]. Despite advances in
diagnostic approaches, staging and treatment,
the overall 5-year survival for lung cancer has
not significantly changed and is estimated to be
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around 16% [3]. This is despite the fact that
early-detected lung cancer is curable in patients
with good performance status. However, the
lack of early detection and accurate localization
of lesion for tissue acquisition remains one of
the biggest challenges in lung cancer
management. Indeed, a recently published
multicenter early detection screening trial
performed using low-dose computerized
tomography (CT) has shown the benefit of
early detection in a selected high-risk cohort
of patients [4]. Screening with low-dose CT
results in a relative reduction of 20% mortality;
however, 96.4% of nodules detected are false
positive and 90.4% of those required further
diagnostic investigations [4]. Choosing the
most appropriate biopsy technique for
suspected peripheral nodule can be a
challenging clinical risk–benefit decision and
factors such as tumor size, location, patient
co-morbidities including emphysematous
changes around the lesion, respiratory
function and the pre-test probability of
malignancy must be taken into account [5–7].
Newer technologies, such as radial probe
endobronchial ultrasound (Rp-EBUS), have the
advantage of locating the peripheral suspicious
lung lesion for cancer; however, they require
the operator to have experience, special
training, and memory of the
three-dimensional tracheobronchial tree.
Rp-EBUS does not provide guidance to the
bronchoscopist for choosing the correct airway
to get to the target lesions; therefore, the overall
diagnostic yield is low and operator dependent
without the assistance of navigation. Recent
advances in navigation systems, based on CT
images and devices used to track the position of
the bronchoscope, have improved the success
rate for the diagnosis of peripheral lung lesion
and are recommended in the American College
of Chest Physicians (ACCP) guidelines where
equipment and expertise are available [7]. As
these procedures are performed in a standard
bronchoscopic suite, in combination with
endobronchial ultrasound-guided
transbronchial needle aspiration (EBUS-TBNA)
of mediastinal lymph nodes, they may provide
a route to complete bronchoscopic thoracic
diagnosis and staging of lung cancer during a
procedure. Thus in a patient with a peripheral
lung nodule and adenopathy, if EBUS-TBNA of
mediastinal nodes were negative for cancer,
under the same anesthesia the peripheral lesion
could be biopsied. However more importantly,
these techniques may provide a platform for
safer localized therapy for lung cancer. The aim
of this paper is to provide an overview of the
recent navigation technologies and their
clinical applications. This article is based on
previously conducted studies and does not
involve any new studies of human or animal





needle aspiration is one of the most frequently
performed procedures, with the diagnostic yield
approaching 65–90%, it is limited due to its
complications, in particular pneumothorax,
requiring chest tube placement and
hospitalization in almost half of the patients
in some studies [8–10] (Table 1). Another
method, video-assisted thoracic surgery
(VATS), is considered a more invasive
procedure for the diagnosis of peripheral
pulmonary lesion and has its own constraints
in terms of cost, duration of the procedure,
localization of small nodules during the
procedure, single lung ventilation and
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requirement of general anesthesia [11]. It is not
a practical approach for all patients with lung
nodules suspicious for cancer.
Although routine flexible bronchoscopy has
been a conventional method to evaluate
peripheral lung nodule, it is of limited
diagnostic value [12] with the diagnostic yield
ranging from 20% to 84% [13–15]. Success is
further compromised if the lesion is smaller
than 2 cm [15], due to the inability to go
beyond the subsegmental level and to steer
endobronchial accessories directly into the
lesion.
Therefore to investigate and establish the
diagnosis of suspicious lung lesions, particularly
located beyond the subsegmental level in the
lung, there is a need for a safer and more
accurate procedure, not only for early diagnosis
of the lesion with less complications, but also to
avoid unnecessary delay and surgical
procedures. Virtual bronchoscopy is one such
CT image-based technique that helps
bronchoscopists to get to the lesion. It also
forms the basis of novel navigation
bronchoscopy technology.
Virtual bronchoscopy (VB) is a
computer-guided bronchoscopy simulation
facilitated by pre-procedural CT imaging. It
provides the same view, angles and zoom
settings as real-time bronchoscopy. It is the
name given to the indirect and augmented
reality visualization of the tracheobronchial tree
from the spatial information derived from CT
images. A key factor that determines airway




























65–90% 20–84% Unknown 70% 44–79% 70% Unknown
Pneumothorax 15–43% Rare Rare 1% 1.5% 1.5–3.5% Unknown
Cost ?c ? ??c ?? ?? ???c Unknown
BTPNA bronchoscopic, CT-TTNA computerized tomography-guided transthoracic needle aspiration, EBUS endobronchial
ultrasound, ENB electromagnetic navigation, TBNA transbronchial needle aspiration, VB virtual bronchoscopy, TPNA
transparenchymal nodule access
a CT-TTNA is used to access the anterior mediastinal nodes
b A larger radial probe EBUS device is used rarely to guide TBNA of mediastinal nodes; however, it has been replaced by
the dedicated EBUS-TBNA scope
c CT-TTNA and standard bronchoscopy are common practice. ?, ?? and ??? are based on initial outlay and cost of
consumables. ? is an indicative sign and reflects basic cost, ?? is higher and ??? reflects expensive and additional cost
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segmentation and accessible number of
branches of the tracheobronchial tree is the
quality of the CT image. A good quality CT
provides detailed airway segmentation.
Airway segmentation is the process of:
1. automated identification of the airways on
each CT slice, with their walls outlined
using ‘‘threshold’’ values, so that the
computer can recognize the outlined
region as airway;
2. the extraction of the identified and the
structures outlined from the rest of the
image using labels;
3. stacking together of these labeled images as
a 3D airway tree.
Specific CT construction image parameters that
provide good quality 3D volume, and
subsequently detailed airway segmentation
and virtual bronchoscopy, are under
investigation and development [16]. However,
a CT that is appropriately collimated to thin
slices (0.5–1 mm) and overlaps the image
reconstruction is generally used to prepare the
VB images down to the peripheral bronchi [16,
17].
There are two VB systems commercially
available: the BF-NAVI system (Cybernet
System Inc., Tokyo, Japan) and the
LungPoint system (Broncus Medical,
Mountain View, CA, USA) (Fig. 1). The
BF-NAVI has been more extensively studied in
humans, whereas LungPoint has limited data in
pre-human studies [18, 19]. The efficacy of VB is
variable in the diagnosis of peripheral lung
lesions. It has been reported in the range of
44.4–78.9% [20]. When combined with
fluoroscopy, VB has not shown improvement
in diagnostic yield with an experienced
bronchoscopist [21]. However, when used with
radial probe EBUS for peripheral lesions
exhibiting involved bronchi on CT, VB has
been shown to improve the diagnostic yield to
94.4% vs. 77.8% [22, 23].
The main advantage of this system over
electromagnetic navigation and radial probe
ultrasound is the lower cost including
consumables. Furthermore, during the
procedure, virtual bronchoscopy provides
information of the airways, where video
display of the tracheobronchial tree is not
available in real time due to either blood,
mucus or airway swelling. The main
disadvantage of virtual bronchoscopy is its
limitation to guide distal smaller airways, lack
of real-time position and characterization of
lesions. In cases where the bronchoscope does
not reach the lesion, there is no additional
guidance. It does not facilitate any remote
steering or directional guidance from the
operator and essentially matches the virtual
model to the airway’s actual model without any
suitability for tool guidance. Therefore, it is
frequently combined with additional guidance
modality such as electromagnetic navigation





(ENB) is an image-based novel technology that
includes the use of virtual bronchoscopy and
facilitates approaching peripheral lung lesions
and mediastinal lymph nodes, which are
difficult to access with conventional
bronchoscopy. The components of the ENB
are (Fig. 2):
• electromagnetic emitter and tracking board,
• sensor (locatable guide wire),
• EWC (extended working channel),
• CT lung model, and
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• Computer-based software.
The electromagnetic emitter and tracking
board emits electromagnetic waves that are not
affected by air or tissue due to their low
frequency (\30 kHz). This creates a magnetic
field around the thorax of the patient, in which
a sensor position can be tracked with a high
degree of accuracy (\1 mm) [24]. The size of the
emitter board and the emitted magnetic field
covers the region of interest (thorax, in case of
bronchoscopy). The magnetic field can be
affected by metal or ferromagnetic interference
in the area, which reduces the accuracy;
therefore, it needs to be optimally calibrated
to the surroundings before clinical use. In
commercially available systems, the sensor is
usually located at the tip of a flexible cable
called a locatable guide (LG) that is covered in a
sheath and passed through the working channel
of the scope (EWC). The sensor transfers the
information regarding its position, planes and
orientation to a computer-based software. The
software displays windows of multiple plans on
the screen to help navigation toward the target
lesion (Fig. 3). Information on location,
orientation and movement is superimposed on
a previously acquired CT scan and displayed on
a monitor in real time [25].
Procedure
The procedure is performed in several steps:
planning, registration and the navigational
bronchoscopy. Planning involves the import
of CT images in the software on a storage device
or through network, in the Digital Imaging and
Communications in Medicine (DICOM) format.
The CT images are processed through software
Fig. 1 Virtual bronchoscopy navigation system. Real-time
guidance with LungPoint Virtual Bronchoscopic
Navigation simultaneously shows the virtual views and
the navigation path. The dark pink area is the target
selected as target 1. The blue line indicates the navigation
path leading toward the target (courtesy Broncus
LungPoint)
584 Adv Ther (2016) 33:580–596
that presents the CT image in axial, coronal and
sagittal cuts and also provides VB images and
the target lesions (lung nodule, mediastinal
lymph nodes). The target lesion or lesions are
marked by the bronchoscopist to plan the best
possible pathway by identifying the bronchial
bifurcation leading toward the target and
placing the anatomical waypoints. The virtual
environment depends on the quality of the CT
images; therefore, it is important to plan the
procedure in greater detail. If the particular
format is unavailable as per manufacturer’s
recommendations, then a repeat CT scan is
required to utilize the software and technology.
Once the appropriate pathway is established,
the bronchoscopist confirms it by running it in
VB and 3D re-constructed tracheobronchial
anatomical model, simultaneously following it
in the integrated CT images. The planning data
can be transferred onto a storage device such as
a USB and/or to the computer based in the
bronchoscopy room. Before performing the
procedure, CT images and both the virtual and
real patient environment are aligned and
integrated to improve the accuracy of
navigation in a process called image to patient
‘‘Registration’’. Registration accuracy is
measured as the average fiducial target
Fig. 2 Our electromagnetic navigation system [16, 25, 33,
34]. In our live porcine model, the essential components of
an Electromagnetic Navigation System are labeled. a In a
similar manner to Fig. 1, using preloaded data from a
standard CT thorax, computer-based software provides
virtual bronchoscopy images in a multiplanar working
window (monitor screen). b An electromagnetic emitter
and tracking board (green) creates a magnetic field around
the chest (blue). c This allows tracking of a sensor probe in
the extended working channel of a standard bronchoscope.
Coupling of this system to the virtual bronchoscopic
images guides movement of the probe to the target lesion.
The placement of our probe in a flexible catheter allows
passage of standard bronchoscopic instruments and biopsy.
d Our research includes the investigation of automation
and remote control of our sensor probe and catheter.
EWC extended working channel
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registration error (AFTRE) and should be\5 mm.
Registration should be repeated in cases where it
is[5 mm, as it signifies unacceptable divergence
between the CT and patient anatomy [26, 27].
Navigation is then performed by inserting the
sensor probe (covered usually with an external
guide sheath) through the working channel of
the bronchoscope, thus forming an EWC. From
the procedure screen, the operator can choose
from multiple available views at different stages
of the procedure to fit the purpose of accurate
navigation of the target lesion. The position of
the probe is simultaneously displayed in all
viewpoints. Once the target is located, the
EWC is locked on the bronchoscope; the
flexible probe can be removed leaving behind
the sheath at the same location for tissue
sampling. Various instruments can be
introduced through the guide sheath including
biopsy forceps, needle and brush. This
technology can also guide fiducial placement
for targeted therapy [28–30].
There are two commercially available
systems that provide ENB: i-LogicTM
(Covedien, Minneapolis, USA) and SPiNDrive
(Veran Medical Technologies, Inc., St Louis,
MO, USA). The major differences between the
two are the electromagnetic emitter board and
the sensor device. The electromagnetic emitter
board used in the i-Logic system is placed
underneath the patient, whereas in SPiNDrive
the field is projected from above the patients.
Fig. 3 Our electromagnetic navigation system multiplanar
window. a Real-time bronchoscopy image and the sensor
probe. b Virtual bronchoscopy image and the navigation
pathway (green line) toward the target lesion. c 3D
tracheobronchial anatomical model. d, e, f Axial, sagittal
and coronal images displaying the sensor location in the
computerized tomography images [25]
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The Sensor device in the i-Logic system (LG) is
as described above: that is, a probe that can be
passed through the working channel of the
bronchoscope with a catheter guided sheath
which comes in various angles (45, 90 and 180)
and offers manual steerability during
navigation. In contrast, the SPiNDrive system
uses ‘‘Always-On Tip Tracked’’ instruments: tip
tracked aspiration needles, forceps and
navigation guide wires that enable ultrathin
bronchoscopes to be navigated to the
peripheral regions of the lung. Veran Medical
Technologies’ new ‘‘ViewTM Peripheral
Catheter’’ is ‘‘always-on’’ with embedded
electromagnetic sensor in a disposable
catheter that provides real-time guidance
throughout the entire procedure. It is a
phantom bronchoscope catheter with manual
steerability. It has a working channel through
which standard instrumentation and sampling
can be performed and can also accommodate
the use of radial EBUS [31, 32]. Another
interesting feature of the Veran Medical
Technologies is ‘‘percutaneous navigational
platform’’ for tissue sampling during
interventional radiology procedures, in
particular, electromagnetic CT-guided
transthoracic biopsies (E-TTNA) with their
navigational needles. E-TTNA has the
potential to be performed when ENB is
non-diagnostic in the same setting using the
same CT scan that was performed for ENB
procedure planning and performance.
However, at present, there are no clinical
trials available comparing outcomes to
standard CT-guided lung biopsy.
In addition to the above commercially
available electromagnetic navigation systems,
our group has developed a 3D electromagnetic
navigation platform with airway segmentation
and virtual bronchoscopy using an open source
3D slicer environment [25] (Figs. 2, 3). The open
source visualization software (3D Slicer http://
www.slicer.org) was further developed to create
a detailed airway segmentation and virtual
bronchoscopy model from acquired CT images
in the DICOM format [16]. A newly developed
magnetic field emitter board provides tracking
of a semiautomatic locatable sensor catheter in
the working channel of the bronchoscope with
Always-On Tip Tracked sensor and can be
steered both manually and automatically with a
joystick, for accurate localization of peripheral
lung lesion [33].
Our navigational platform has been tested
in vitro using the breathing lung model and
in vivo using a porcine model [25, 34]. The
system is at a developmental stage; however, it
is distinctive due to being an inexpensive and
available open source software. Further work is
being carried out to improve the registration
and accuracy of the navigational system before
a pilot study in patients with peripheral lung
nodules [25].
Diagnostic Yield
The first proof of concept trial to determine the
practicality, accuracy and safety of real-time
ENB in locating artificial peripheral lung lesions
was performed in a swine model in 2003 [35].
The registration accuracy expressed by the
fiducial target registration error, expressing
both the registration quality and the stability
of fiducial (registration) points, was 4.5 mm on
average. ENB was able to successfully reach all
nine target areas. No adverse effects, such as
pneumothorax or internal bleeding, were
encountered in any of the animals in this
study. Real-time electromagnetic navigation
coupled with a pre-procedure CT scan proved
to be an accurate technology that can enhance
the effectiveness of standard bronchoscopy to
assist in reaching peripheral lung lesion.
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Following this, initial human studies were
published in 2005 and 2006; again
demonstrating that the ENB with CT scan is a
feasible and safe method for obtaining biopsies
from peripheral lung lesion. [36, 37] The
diagnostic yield reported in both studies was
69%. No device-related adverse events were
reported. Another study during the same time
period, with a larger patient group,
demonstrated a diagnostic yield of 74%. The
study also reported additional applicability of
sampling mediastinal lymph nodes with the use
of ENB. Since then, a number of studies have
added evidence to the use of ENB for the
accurate diagnosis of peripheral lung lesion. A
recent meta-analysis reported the diagnostic
range from 49% to 87.5% and the pooled
diagnostic yield of 64.9%. The diagnostic
accuracy was 73.9%, ranging from 59.0% to
93.1% [38–40]. A meta-analysis of the selected
16 studies showed that the median diameter
was 25 mm and the median distance to the
pleural surface was 11 mm. Thirty-eight percent
of nodules were located in the lower lobes. The
sensitivity to detect cancer was 71.1% (95% CI
64.6–76.8), with a negative predictive value of
52.1% (95% CI 43.5–60.6) [40].
Safety Profile of ENB
The main complication reported is
pneumothorax (3.5%) which is considerably
lower than that with TTNA [8] and reflects the
superior safety profile of ENB. In few cases,
hypoxemia and minor bleeding have been
reported; however, no procedure or
sedation-related death has been published
[26–28]. In a small case series of fiducial
placement, ENB is safe and the pneumothorax
rate is smaller than with the transcutaneous
implantation of fiducial placement [28–30]. The
safety of pacemakers and defibrillators in ENB
has been studied in a limited number of
patients. There were no complications
encountered in all 24 successfully concluded
procedures. The plausible explanation for these
results is that the magnetic field in ENB is much
weaker than that used in MRI and therefore
does not interfere with pacemakers and
implanted cardiac devices. However, the
authors concluded that close cardiac
monitoring of patients during and
post-procedure is recommended [41].
Factors Influencing Yield
Despite the improved safety profile, the
diagnostic yield of ENB remains less than that
of TTNA. There are various patient, operator
and technological factors that impact the
diagnostic yield.
Patient and Operator Factors
Firstly, related to lesion, the size and location of
the lesion influences the effectiveness of ENB.
The ENB platform is used for peripheral lung
lesions, although, theoretically, it can be used
to diagnose any suspicious lesion, located
anywhere in the chest. However, it had been
shown [42] that an airway going right into the
lesion on the CT scan (bronchus sign) makes
the lesion accessible to ENB and improves the
diagnostic yield (Fig. 4). If there is no bronchus
sign, it is still possible to get to the lesion, but
the diagnostic yield may not be as good as it
would be if there was a bronchus sign. The
diagnosis was 79% (30/38) in patients with a
bronchus sign on CT imaging, but only in 4/13
(31%) with no discernible bronchus sign [42].
Moreover, the diagnostic yield is higher (88%)
for a lesion located in the right middle lobe
compared to that in the upper or lower lobes
[43]. This may be due to the acute angle of the
corresponding bronchus in the upper lobes and
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respiratory movement in the lower lobes [44].
The size of the lesion is also an independent
factor that determines the diagnostic yield of
the ENB [45]. In a prospective study of 180
consecutive ENB cases, the average lesion
diameter was 29.6 vs. 17.6 mm in the
diagnostic and non-diagnostic groups,
respectively (p = 0.001) [46].
Surprisingly, the diagnostic yield for
peripheral lesions reported in literature, both
for the VB and ENB, is not significantly different
[20–22, 38–40]. This may be due to lack of clear
definition of the peripheral lesion. Pulmonary
nodules are defined as 3 cm or less in size and
surrounded by lung parenchyma [5, 47];
however, the definition of peripheral lesion
lacks clarity in terms of location from the
pleura and whether the lesion is
endobronchially at the distal end of the
tapering bronchus or completely in the lung
parenchyma. The adjacent structures to the
lesion or the distance to the pleura may alter
the diagnostic yield or complication rate of the
procedure. There is a need to clarify and define
the peripheral lung lesion due to rapid
advancements and comparison of different
technologies with variable results [42].
Various other factors that influence the ENB
procedures are sedation or general anesthesia,
availability of rapid onsite cytology, methods of
tissue acquisition and operator experience.
Studies differ with regard to yield with
conscious vs. general anesthesia [38, 43,
48–50]. However, a recent meta-analysis has
shown that the diagnostic yield was better with
the use of general anesthesia (69.2% vs. 57.5%,
p 0.02) [40]. The optimal method remains
arguable and also depends on local expertise.
Rapid on-site cytology (ROSE) utilizes
immediate analysis of the aspirated specimens
and provides instant feedback about the
specimen quality and diagnosis. The use of
ROSE improves the diagnostic yield [40, 51, 52].
The methods of tissue acquisition have also
been studied; catheter aspiration compared to
traditional practice of forceps biopsy has been
shown to have higher diagnostic yield in one
study (90% vs. 50%) [53]. However, similar to
the research of diagnostic tools in radial probe
ultrasound, a broad armamentarium for
sampling is better once the lesion has been
accurately localized. Further research is required
with regard to the optimal combination of
sampling techniques. The learning curve for
ENB is variable and operator dependent. The
centers using ENB have demonstrated higher
diagnostic yield with improvement in operator
experience [54]
Technological Factors
Not surprisingly, factors that have affected the
outcome of the procedure are related to the
technology itself, including the AFTRE score.
Low AFTRE \5 mm indicates less CT to patient
divergence and improved registration, and
results in better diagnostic accuracy [26, 27].
Various other technological factors that have
Fig. 4 An 81-year-old lady with bilateral lung nodules.
Axial computerized tomography scan shows a positive
bronchus sign [red arrow right upper lobe posterior
segment (RB2)] related to a mass in her right upper lobe
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been studied are CT configuration and
optimization (reconstruction kernel, radiation
dose and slice thickness) for detailed 3D
segmentation [16], and the improvement of
software to make it user friendly and
cost-effective to help clinicians incorporate
this technology in their practice.
COMPLEMENTARY TECHNOLOGIES
Radial Probe EBUS
Combined modalities can overcome the
limitations of individual techniques. A
technology that complements ENB is Rp-EBUS,
in that ENB provides the guidance lacking in
Rp-EBUS. A meta-analysis of Rp-EBUS identified
a sensitivity of 73% with a pneumothorax rate
of 1%; however, the selection of patients
included in these trials must be taken into
account [55]. A subsequent meta-analysis of
guided bronchoscopy for the evaluation of the
pulmonary nodule for all bronchoscopic
modalities identified similar sensitivity for
lung cancer and complication rates [56].
Combining ENB and Rp-EBUS, Rp-EBUS may
provide better visualization and a further degree
of certainty that the target has been reached.
Rp-EBUS is performed by placing the tip of a
20 MHz miniature ultrasonic radial probe at the
site of the lesion through the working channel
of the bronchoscope. A prospective randomized
trial has shown an improved diagnostic yield of
88% with a combination of ENB and Rp-EBUS,
in comparison to Rp-EBUS alone (69%) and ENB
alone (59%) [38]. Both fluoroscopy and ROSE
were not used during the study. Moreover, there
was significantly less bleeding and the
pneumothorax rate was 8% in the combined
ENB/Rp-EBUS procedure [8, 57]. Another trial
combining the VB and Rp-EBUS in patients with
a positive bronchus sign (Fig. 4) showed that
the diagnostic yield in the VB and non-VB
groups was 94.4% vs. 77.8% (p = 0.004),
respectively, particularly high for lesions
smaller than 20 mm (94.6% vs. 70.7%;
p = 0.006) [22]. A more recent trial suggested
that the use of ENB after bronchoscopy, with a
combination of Rp-EBUS and VB, led to a small
increased yield with an overall yield of 70%
[29]. As before, probe position and lesion size
influenced diagnostic yield; the authors suggest
using all available modes of sampling when the
lesion is reached. In interpreting trials, the
expertise of the individual bronchoscopist
must be considered and multicenter
standardized comparisons would be extremely
helpful in clarifying the best diagnostic
pathway for peripheral lung nodules.
Additionally, multimodality guidance for
bronchoscopic insertion of fiducial markers
has been used successfully and safely for
accurate external beam stereotactic radiation
treatment [29, 30]. Intratumor localization of
fiducial marker placement was superior and the
complications including fiducial migration and
pneumothorax were less, compared to the
percutaneous fiducial lung implantation in the
multimodality group [29, 30]. Overall,
combining multimodalities in one procedure
are of great interest for the future development
of navigational technology.
ULTRATHIN BRONCHOSCOPY
Ultrathin bronchoscopy (UTB) allows reaching
the bronchial tree beyond the conventional
bronchoscope. It has an outer diameter of
around 3 mm and the inner working channel
diameter of just over 1 mm (1.2 mm). This
allows deeper access into the endobronchial
tree. However, given the thin and malleable
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nature of the scope with small working channel,
it may pose difficulty in maneuvering through
distal airways. A recent comparative trial for
peripheral pulmonary lesion in 310 patients,
combining either UTB or thin bronchoscopy
(TB) that has external diameter of 4 mm with
EBUS, fluoroscopy and VB has shown higher
diagnostic histologic specimens in UTB vs. TB




One of the limitations of ENB is the challenge of
accessing the nodules, which are eccentrically
positioned and may not have the airway
directly leading to them. To overcome this, a
novel navigational approach, bronchoscopic
transparenchymal nodule access (BTPNA) has
been recently developed [59–61]. In this
technique, the nodules are accessed through a
transparenchymal ‘‘off-road’’ approach that is
not dependent on the need to have an airway
leading into the lesion. A computer
software-generated tunneled path is created
from the bronchial segments through the lung
parenchyma directly to the peripheral lung
lesions (Fig. 5). A pilot study in a human
population has demonstrated the safety and
feasibility with adequate sampling and a yield
of 83% (10/12 lesions) [59]. The mean
transparenchymal tunnel size was 47 mm
(10–90 mm), and an average of 3.3 samples
was obtained in 12 patients. In this study,
Archimedes Virtual Bronchoscopy Navigation
System (Broncus Medical, Mountain View, CA,
USA) was used in combination with
computer-enhanced fused fluoroscopy. The
mean fluoroscopy time was 5.5 (range
1.8–11.6) min. There was no pneumothorax or
significant complications apart from transient
troponin leak. However, in 2 out of 12 patients,
the track could not be created [59]. BTPNA relies
on the operator experience and the software to
ensure that no major vessels are injured while
tunneling through the lung parenchyma.
Further data to compare BTPNA against the





At present, bronchoscopic-guided therapy for
lung cancer is limited to debulking of malignant
airway obstruction with a number of different
techniques including electrocautery [62] and
treatment of early in situ cancer for the airways
[62]. However, given the access to cancer
through novel bronchoscopic techniques,
there is a growing interest in
bronchoscopic-guided therapy for early lung
cancer, such as brachytherapy microwave
ablation and radiofrequency ablation.
At present to our knowledge, only one group
has presented their experience in a small case
series. Delivery of cancer-directed therapy
(brachytherapy) by ENB guidance has been
demonstrated in the major airways [63, 64].
However, the performance of this technique in
comparison to standard therapy is not clear and
continues to remain a potential research area.
COST ANALYSIS
There have been limited cost analysis studies of
these techniques. It is widely accepted that
CT-TTNA is cost-effective in comparison to
VATS biopsy, especially with the availability of
positron emission tomography-CT [65].
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Another study applied a decision tree analysis to
compare downstream costs of Rp-EBUS with
CT-TTNA [66]. The costs of Rp-EBUS and
CT-TTNA appeared to be equivalent (US$2724
vs. US$2748), and the authors suggested that
specific clinical–radiologic factors such as a
positive bronchus sign and location of the
lesion influence cost–benefit outcomes.
Further evaluation of patient preferences and
their influence on cost-effectiveness were
recommended. Finally, another study using
100 hypothetical patients created a decision
tree with values from the literature to evaluate
the clinical consequences and societal costs of a
CT-TTNA versus ENB biopsy diagnosis of an SPN
[67]. The authors concluded that an ENB with
biopsy strategy is associated with decreased
pneumothorax rate, but increased costs (by
3719US$ per case) and increased use of VATS
(by 20%). Combining CT-guided biopsy and
ENB with biopsy serially can decrease costs and
complications. This, however, is clearly a
significant cost increase and needs to be
investigated further (Table 1). Ideally, a
strategy combining EBUS-TBNA of mediastinal
lymph nodes followed by sequential guided
biopsy techniques should be compared to
separate mediastinal sampling plus CT-TTNA.
Improvements in dedicated EBUS scope such as
reduction in size and increased angulation will
allow bronchoscopists to use this device to
biopsy more peripheral lung lesions [68].
Fig. 5 Bronchoscopic transparenchymal nodule access
(courtesy Broncus ArchimedesTM). a Real-time
bronchoscopic image showing catheter at the point of
entry. b Real-time virtual image with point of entry
overlaid. Green area indicates target lesion. The vertical
colored lines on the left of the virtual bronchoscopy indicate
the distance in the airway, tunnel length, size of the target
and distance from the pleura. c Computerized tomography
projections with target and vessel overlay. Red and blue
colors indicate vessels. The target is marked green. d 3D
reconstruction of the airway tree
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CONCLUSIONS
In conclusion, navigational bronchoscopic
techniques are an exciting advancement that
improves the success in the diagnosis of
peripheral lung lesion. They allow a ‘‘one-stop
shop’’ of accurate bronchoscopic assessment of
both the mediastinum through EBUS or ENB
and the peripheral lesion. However,
improvements are required in accuracy, and
the procedure is currently expensive
particularly after adding the expense of
obtaining additional thin-slice CT prior to the
procedure and the disposable equipment that
further drives up the cost.
These techniques appear safe and promising,
not only for the diagnosis of peripheral lung
lesion, but also holds hopes for therapeutic
applications like microwave ablation,
radiofrequency ablation and brachytherapy.
ACKNOWLEDGMENTS
No funding or sponsorship was received for this
study or publication of this article. All named
authors meet the International Committee of
Medical Journal Editors (ICMJE) criteria for
authorship for this manuscript, take
responsibility for the integrity of the work as a
whole and have given final approval for the
version to be published.
Disclosures. Kashif Ali Khan, Pietro Nardelli,
Alex Jaeger, Conor O’Shea, Padraig
Cantillon-Murphy and Marcus P. Kennedy
have nothing to disclose.
Compliance with Ethics Guidelines. This
article is based on previously conducted
studies and does not involve any new studies
of human or animal subjects performed by any
of the authors.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommercial
use, distribution, and reproduction in any
medium, provided you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons license, and
indicate if changes were made.
REFERENCES
1. Siegel R, Ward E, Brawley O, et al. Cancer statistics,
2011: the impact of eliminating socioeconomic and
racial disparities on premature cancer deaths. CA
Cancer J Clin. 2011;61(4):212–36.
2. Jemal A, Bray F, Center MM, et al. Global cancer
statistics. CA Cancer J Clin. 2011;61(2):69–90.
3. Goldstraw P, Crowley J, Chansky K, et al. The IASLC
Lung Cancer Staging Project: proposals for the
revision of the TNM stage groupings in the
forthcoming (seventh) edition of the TNM
classification of malignant tumours. J Thorac
Oncol. 2007;2(8):706–14.
4. National Lung Screening Trial Research T, Aberle
DR, Adams AM, et al. Reduced lung-cancer
mortality with low-dose computed tomographic
screening. N Engl J Med. 2011;365(5):395–409.
5. Gould MK, Donington J, Lynch WR, et al.
Evaluation of individuals with pulmonary
nodules: when is it lung cancer? Diagnosis and
management of lung cancer, 3rd ed: American
College of Chest Physicians evidence-based
clinical practice guidelines. Chest. 2013;143(5
Suppl):e93S–120S.
6. Ost DE, Yeung SC, Tanoue LT, et al. Clinical and
organizational factors in the initial evaluation of
patients with lung cancer: diagnosis and
management of lung cancer, 3rd ed: American
College of Chest Physicians evidence-based
clinical practice guidelines. Chest. 2013;143(5
Suppl):e121S–41S.
7. Detterbeck FC, Lewis SZ, Diekemper R, et al.
Executive Summary: diagnosis and management
of lung cancer, 3rd ed: American College of Chest
Physicians evidence-based clinical practice
guidelines. Chest. 2013;143(5 Suppl):7S–37S.
Adv Ther (2016) 33:580–596 593
8. Khan KA, Zaidi S, Swan N, et al. The use of
computerised tomography guided percutaneous
fine needle aspiration in the evaluation of
solitary pulmonary nodules. Ir Med J.
2012;105(2):50–2.
9. Santambrogio L, Nosotti M, Bellaviti N, et al.
CT-guided fine-needle aspiration cytology of
solitary pulmonary nodules: a prospective,
randomized study of immediate cytologic
evaluation. Chest. 1997;112(2):423–5.
10. Laurent F, Michel P, Latrabe V, et al.
Pneumothoraces and chest tube placement after
CT-guided transthoracic lung biopsy using a coaxial
technique: incidence and risk factors. AJR Am J
Roentgenol. 1999;172(4):1049–53.
11. Gould MK, Sanders GD, Barnett PG, et al.
Cost-effectiveness of alternative management
strategies for patients with solitary pulmonary
nodules. Ann Intern Med. 2003;138(9):724–35.
12. Baaklini WA, Reinoso MA, Gorin AB, et al.
Diagnostic yield of fiberoptic bronchoscopy in
evaluating solitary pulmonary nodules. Chest.
2000;117(4):1049–54.
13. Funakoshi Y, Sawabata N, Takeda S, et al.
Bronchoscopically undiagnosed small peripheral
lung tumors. Interact CardioVasc Thorac Surg.
2003;2(4):517–20.
14. Shiner RJ, Rosenman J, Katz I, et al. Bronchoscopic
evaluation of peripheral lung tumours. Thorax.
1988;43(11):887–9.
15. Schreiber G, McCrory DC. Performance
characteristics of different modalities for diagnosis
of suspected lung cancer: summary of published
evidence. Chest. 2003;123(1 Suppl):115S–28S.
16. Nardelli P, Khan KA, Corvo A, et al. Optimizing
parameters of an open-source airway segmentation
algorithm using different CT images. Biomed Eng
Online. 2015;14:62.
17. Neumann K, Winterer J, Kimmig M, et al. Real-time
interactive virtual endoscopy of the
tracheo-bronchial system: influence of CT imaging
protocols and observer ability. Eur J Radiol.
2000;33(1):50–4.
18. Merritt SA, Gibbs JD, Yu KC, et al. Image-guided
bronchoscopy for peripheral lung lesions: a
phantom study. Chest. 2008;134(5):1017–26.
19. Dolina MY, Cornish DC, Merritt SA, et al.
Interbronchoscopist variability in endobronchial
path selection: a simulation study. Chest.
2008;133(4):897–905.
20. Asano F, Eberhardt R, Herth FJ. Virtual
bronchoscopic navigation for peripheral
pulmonary lesions. Respiration. 2014;88(5):430–40.
21. Tachihara M, Ishida T, Kanazawa K, et al. A virtual
bronchoscopic navigation system under X-ray
fluoroscopy for transbronchial diagnosis of small
peripheral pulmonary lesions. Lung Cancer.
2007;57(3):322–7.
22. Asano F, Shinagawa N, Ishida T, et al. Virtual
bronchoscopic navigation improves the diagnostic
yield of radial-endobronchial ultrasound for
peripheral pulmonary lesions with involved
bronchi on CT. Intern Med. 2015;54(9):1021–5.
23. Oshige M, Shirakawa T, Nakamura M, et al. Clinical
application of virtual bronchoscopic navigation
system for peripheral lung lesions. J Bronchol
Interv Pulmonol. 2011;18(2):196–202.
24. O’Donoghue K, Cantillon-Murphy P. Low cost
super-Nyquist asynchronous demodulation for use
in EM tracking systems. IEEE Trans Instrum
Measure. 2014;64(2):458–66.
25. Khan KA, Nardelli P, Alex J, O’Shea C,
Cantillon-Murphy P, Kennedy MP. The design and
validation of a novel semiautomatic lung navigation
platform. Thorax. 2015;70(Supple 3):A220.
26. Makris D, Scherpereel A, Leroy S, et al.
Electromagnetic navigation diagnostic
bronchoscopy for small peripheral lung lesions.
Eur Respir J. 2007;29(6):1187–92.
27. Makris D, Gourgoulianis KI. Electromagnetic
navigation diagnostic bronchoscopy and
transbronchial biopsy. Chest. 2008;133(3):829–30.
28. Hagmeyer L, Priegnitz C, Kocher M et al. Fiducial
marker placement via conventional or
electromagnetic navigation bronchoscopy (ENB):
an interdisciplinary approach to the curative
management of lung cancer. Clin Respir J. 2014.
doi:10.1111/crj.12214
29. Steinfort DP, Siva S, Kron T, et al. Multimodality
guidance for accurate bronchoscopic insertion of
fiducial markers. J Thorac Oncol. 2015;10(2):324–30.
30. Schroeder C, Hejal R, Linden PA. Coil spring fiducial
markers placed safely using navigation
bronchoscopy in inoperable patients allows
accurate delivery of CyberKnife stereotactic
radiosurgery. J Thorac Cardiovasc Surg.
2010;140(5):1137–42.
31. von Jako RA, Carrino JA, Yonemura KS, et al.
Electromagnetic navigation for percutaneous
guide-wire insertion: accuracy and efficiency
594 Adv Ther (2016) 33:580–596
compared to conventional fluoroscopic guidance.
Neuroimage. 2009;47(Suppl 2):T127–32.
32. http://www.veranmedical.com/view-catheter.html.
Accessed 12 Aug 2015.
33. O’Donoghue K, Corvo A, Nardelli P, et al.
Evaluation of a novel tracking system in a
breathing lung model. Conf Proc IEEE Eng Med
Biol Soc. 2014;2014:4046–9.
34. O’Shea C, Khan KA, Kennedy MP, Nardelli P,
Cantillon-Murphy P. Evaluation of endoscopically
deployed radiopaque tumour models in
bronchoscopy. J Bronchol Interv Pulmonol
(Manuscript accepted).
35. Schwarz Y, Mehta AC, Ernst A, et al.
Electromagnetic navigation during flexible
bronchoscopy. Respiration. 2003;70(5):516–22.
36. Schwarz Y, Greif J, Becker HD, et al. Real-time
electromagnetic navigation bronchoscopy to
peripheral lung lesions using overlaid CT
images: the first human study. Chest.
2006;129(4):988–94.
37. Becker HD, Herth F, et al. Bronchoscopic biopsy of
peripheral lung lesions under electromagnetic
guidance. A pilot study. J Bronchol Interv
Pulmonol. 2005;12:9–13.
38. Eberhardt R, Anantham D, Ernst A, et al.
Multimodality bronchoscopic diagnosis of
peripheral lung lesions: a randomized controlled
trial. Am J Respir Crit Care Med. 2007;176(1):36–41.
39. Lamprecht B, Porsch P, Wegleitner B, et al.
Electromagnetic navigation bronchoscopy (ENB):
Increasing diagnostic yield. Respir Med.
2012;106(5):710–5.
40. Gex G, Pralong JA, Combescure C, et al. Diagnostic
yield and safety of electromagnetic navigation
bronchoscopy for lung nodules: a systematic
review and meta-analysis. Respiration.
2014;87(2):165–76.
41. Khan AY, Berkowitz D, Krimsky WS, et al. Safety of
pacemakers and defibrillators in electromagnetic
navigation bronchoscopy. Chest. 2013;143(1):75–81.
42. Seijo LM, de Torres JP, Lozano MD, et al. Diagnostic
yield of electromagnetic navigation bronchoscopy
is highly dependent on the presence of a Bronchus
sign on CT imaging: results from a prospective
study. Chest. 2010;138(6):1316–21.
43. Eberhardt R, Anantham D, Herth F, et al.
Electromagnetic navigation diagnostic
bronchoscopy in peripheral lung lesions. Chest.
2007;131(6):1800–5.
44. Chen A, Pastis N, Furukawa B, et al. The effect of
respiratory motion on pulmonary nodule location
during electromagnetic navigation bronchoscopy.
Chest. 2015;147(5):1275–81.
45. Jensen KW, Hsia DW, Seijo LM, et al. Multicenter
experience with electromagnetic navigation
bronchoscopy for the diagnosis of pulmonary
nodules. J Bronchol Interv Pulmonol.
2012;19(3):195–9.
46. Ortega PR, Gutiérrez JG, Juárez ÁOR, Arias HDQ,
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